Quetiapine -SIL NDSRI
References
FAQ's
References
- Warawa, Edward John; Migler, Bernard Martin, Thiazepine compounds, ICI Americas, Inc., United States, EP0240228A1, October 7, 1987
- Mandrioli, R.; Fanali, S.; Ferranti, A.; Raggi, M. A., HPLC analysis of the novel antipsychotic drug quetiapine in human plasma, Journal of Pharmaceutical and Biomedical Analysis, Volume: 30, Issue: 4, Pages: 969-977, 2002
Frequently Asked Questions
Are there any specific Quetiapine impurities for monitoring?
All Quetiapine impurities are monitored strictly during the process.
How are Quetiapine impurities detected during the manufacturing process?
Quetiapine impurities are examined during quality control testing by employing analytical techniques to identify and quantify the impurities present in the Quetiapine.
What are the temperature conditions required to store Quetiapine impurities?
Quetiapine impurities are stored preferably at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.